Jaden D Evans1, Lindsay K Morris1, Henan Zhang2, Siyu Cao2, Xin Liu2, Kristin C Mara3, Bradley J Stish1, Brian J Davis1, Aaron S Mansfield4, Roxana S Dronca5, Matthew J Iott1, Eugene D Kwon6, Robert L Foote1, Kenneth R Olivier1, Haidong Dong7, Sean S Park8. 1. Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota. 2. Department of Immunology, Mayo Clinic, Rochester, Minnesota. 3. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota. 4. Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota. 5. Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota; Division of Medical Oncology, Mayo Clinic, Jacksonville, Florida. 6. Department of Urology, Mayo Clinic, Rochester, Minnesota. 7. Department of Immunology, Mayo Clinic, Rochester, Minnesota; Department of Urology, Mayo Clinic, Rochester, Minnesota. 8. Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota. Electronic address: park.sean@mayo.edu.
Abstract
PURPOSE: This study examined the effects of metastasis-directed stereotactic body radiation therapy (mdSBRT) on CD8+ T-cell subpopulations and correlated post-mdSBRT immunophenotypic responses with clinical outcomes in patients with oligometastatic prostate cancer (OPCa). METHODS AND MATERIALS: Peripheral blood mononuclear cells were prospectively isolated from 37 patients with OPCa (≤3 metastases) who were treated with mdSBRT. Immunophenotyping identified circulating CD8+ T-cell subpopulations, including tumor-reactive (TTR), effector memory, central memory (TCM), effector, and naïve T cells from samples collected before and after mdSBRT. Univariate Cox proportional hazards regression was used to assess whether changes in these T-cell subpopulations were potential risk factors for death and/or progression. The Kaplan-Meier method was used for survival. Cumulative incidence for progression and new distant metastasis weas estimated, considering death as a competing risk. RESULTS: Median follow-up was 39 months (interquartile range, 34-43). Overall survival at 3 years was 78.2%. Cumulative incidence for local progression and new distant metastasis at 3 years was 16.5% and 67.6%, respectively. Between baseline and day 14 after mdSBRT, an increase in the TCM cell subpopulation was associated with the risk of death (hazard ratio, 1.22 [95% confidence interval, 1.02-1.47]; P = .033), and an increase in the TTR cell subpopulation was protective against the risk of local progression (hazard ratio, 0.80 [95% confidence interval, 0.65-0.98]; P = .032). CONCLUSIONS: An increase in the TTR cell subpopulation was protective against the risk of disease progression, and an increase in the TCM cell subpopulation was associated with the risk of death in patients with OPCa treated with mdSBRT. Disease control may be further improved by better understanding the CD8+ T-cell subpopulations and by enhancing their antitumor effect.
PURPOSE: This study examined the effects of metastasis-directed stereotactic body radiation therapy (mdSBRT) on CD8+ T-cell subpopulations and correlated post-mdSBRT immunophenotypic responses with clinical outcomes in patients with oligometastatic prostate cancer (OPCa). METHODS AND MATERIALS: Peripheral blood mononuclear cells were prospectively isolated from 37 patients with OPCa (≤3 metastases) who were treated with mdSBRT. Immunophenotyping identified circulating CD8+ T-cell subpopulations, including tumor-reactive (TTR), effector memory, central memory (TCM), effector, and naïve T cells from samples collected before and after mdSBRT. Univariate Cox proportional hazards regression was used to assess whether changes in these T-cell subpopulations were potential risk factors for death and/or progression. The Kaplan-Meier method was used for survival. Cumulative incidence for progression and new distant metastasis weas estimated, considering death as a competing risk. RESULTS: Median follow-up was 39 months (interquartile range, 34-43). Overall survival at 3 years was 78.2%. Cumulative incidence for local progression and new distant metastasis at 3 years was 16.5% and 67.6%, respectively. Between baseline and day 14 after mdSBRT, an increase in the TCM cell subpopulation was associated with the risk of death (hazard ratio, 1.22 [95% confidence interval, 1.02-1.47]; P = .033), and an increase in the TTR cell subpopulation was protective against the risk of local progression (hazard ratio, 0.80 [95% confidence interval, 0.65-0.98]; P = .032). CONCLUSIONS: An increase in the TTR cell subpopulation was protective against the risk of disease progression, and an increase in the TCM cell subpopulation was associated with the risk of death in patients with OPCa treated with mdSBRT. Disease control may be further improved by better understanding the CD8+ T-cell subpopulations and by enhancing their antitumor effect.
Authors: Brett W Cox; Daniel E Spratt; Michael Lovelock; Mark H Bilsky; Eric Lis; Samuel Ryu; Jason Sheehan; Peter C Gerszten; Eric Chang; Iris Gibbs; Scott Soltys; Arjun Sahgal; Joe Deasy; John Flickinger; Mubina Quader; Stefan Mindea; Yoshiya Yamada Journal: Int J Radiat Oncol Biol Phys Date: 2012-05-19 Impact factor: 7.038
Authors: A Heiser; M A Maurice; D R Yancey; N Z Wu; P Dahm; S K Pruitt; D Boczkowski; S K Nair; M S Ballo; E Gilboa; J Vieweg Journal: J Immunol Date: 2001-03-01 Impact factor: 5.422
Authors: William P Parker; Brian J Davis; Sean S Park; Kenneth R Olivier; Richard Choo; Mark A Nathan; Val J Lowe; Timothy J Welch; Jaden D Evans; William S Harmsen; Harras B Zaid; Ilya Sobol; Daniel M Moreira; Rimki Haloi; Matthew K Tollefson; Matthew T Gettman; Stephen A Boorjian; Lance A Mynderse; R Jeffrey Karnes; Eugene D Kwon Journal: Eur Urol Date: 2016-09-03 Impact factor: 20.096
Authors: William P Parker; Jaden D Evans; Bradley J Stish; Sean S Park; Kenneth Olivier; Richard Choo; Mark A Nathan; Brian T Welch; R Jeffrey Karnes; Lance A Mynderse; Thomas M Pisansky; Eugene D Kwon; Val J Lowe; Brian J Davis Journal: Int J Radiat Oncol Biol Phys Date: 2016-11-17 Impact factor: 7.038
Authors: Christopher Foster; Douglas Easton; Ultan McDermott; David C Wedge; G Steven Bova; Gunes Gundem; Peter Van Loo; Barbara Kremeyer; Ludmil B Alexandrov; Jose M C Tubio; Elli Papaemmanuil; Daniel S Brewer; Heini M L Kallio; Gunilla Högnäs; Matti Annala; Kati Kivinummi; Victoria Goody; Calli Latimer; Sarah O'Meara; Kevin J Dawson; William Isaacs; Michael R Emmert-Buck; Matti Nykter; Zsofia Kote-Jarai; Hayley C Whitaker; David E Neal; Colin S Cooper; Rosalind A Eeles; Tapio Visakorpi; Peter J Campbell Journal: Nature Date: 2015-04-01 Impact factor: 49.962
Authors: E M Fernández-García; F E Vera-Badillo; B Perez-Valderrama; A S Matos-Pita; I Duran Journal: Clin Transl Oncol Date: 2014-12-06 Impact factor: 3.340
Authors: Igor Tsaur; Roman A Blaheta; Robert Dotzauer; Cristian Mirvald; Jonathan Olivier; Cristian Surcel; Maximilian P Brandt; Giorgio Gandaglia; Ioanel Sinescu Journal: World J Urol Date: 2022-10-02 Impact factor: 3.661
Authors: Henan Zhang; Jacob J Orme; Haidong Dong; Sean S Park; Feven Abraha; B J Stish; Val J Lowe; Fabrice Lucien; Erik J Tryggestad; Michael S Bold; Lance C Pagliaro; C Richard Choo; Debra H Brinkmann; Matthew J Iott; Brian J Davis; J Fernando Quevedo; William S Harmsen; Brian A Costello; Geoffrey B Johnson; Mark A Nathan; Kenneth R Olivier; Thomas M Pisansky; Eugene D Kwon Journal: Clin Cancer Res Date: 2021-09-30 Impact factor: 13.801